Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Color-Tuning Bioluminescent Sensor (AmyLuc) for Real-Time Monitoring of Intracellular pH Dynamics in Cancer Cells.

Analytical chemistry·2026
Same author

Structure-Based Discovery of Obeticholic Acid Derivatives as Novel Farnesoid X Receptor Partial Agonists with Improved Selectivity and Reduced Off-Target Effects.

ChemMedChem·2026
Same author

The secondary bile acid, lithocholic acid, inhibits cystic fibrosis transmembrane conductance regulator expression and activity in colonic epithelial cells.

American journal of physiology. Gastrointestinal and liver physiology·2025
Same author

FFF as a microfluidic platform for the streamlined optimization of ready-to-use nanozyme-labelled probes to enable robust and ultra-sensitive chemiluminescent bioassays.

Biosensors & bioelectronics·2025
Same author

Jagged1-Fluc: A Luminescent Recombinant Protein as a Sensitive Tool for High-Throughput Screening of Colorectal Cancer.

BioFactors (Oxford, England)·2025
Same author

Tryptophan pathway profiling in multiple sclerosis patients treated with ocrelizumab.

Frontiers in immunology·2025

Related Experiment Video

Updated: May 13, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Ursodeoxycholic acid attenuates colonic epithelial secretory function.

Orlaith B Kelly1, Magdalena S Mroz, Joseph B J Ward

  • 1Department of Molecular Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.

The Journal of Physiology
|March 20, 2013
PubMed
Summary

Ursodeoxycholic acid (UDCA) directly reduces colonic epithelial secretion by inhibiting key ion transporters. Stable UDCA derivatives show potential for treating diarrhea associated with bile acid malabsorption.

More Related Videos

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

Related Experiment Videos

Last Updated: May 13, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

Area of Science:

  • Gastroenterology
  • Cell Biology
  • Molecular Physiology

Background:

  • Dihydroxy bile acids, like chenodeoxycholic acid (CDCA), induce colonic secretion and diarrhea.
  • CDCA is converted by gut bacteria to ursodeoxycholic acid (UDCA), whose epithelial transport effects are unclear.

Purpose of the Study:

  • To investigate the role of UDCA in regulating colonic epithelial secretion.
  • To identify the molecular mechanisms underlying UDCA's effects on colonic transport.

Main Methods:

  • Measured chloride secretion in T84 cell monolayers and mouse/human colon sections.
  • Assessed transport protein expression using cell surface biotinylation.
  • Investigated effects of UDCA, lithocholic acid (LCA), and a UDCA analogue (6α-methyl-UDCA) in vitro and in vivo.

Main Results:

  • UDCA acutely inhibited chloride secretion in T84 cells and mouse/human colon.
  • UDCA inhibited Na+/K+-ATPase activity and basolateral K+ channel currents without changing protein expression.
  • In vivo, UDCA enhanced secretion in mice, likely via bacterial conversion to LCA, while a stable analogue showed anti-secretory effects.

Conclusions:

  • UDCA has direct anti-secretory effects on colonic epithelial cells.
  • Metabolically stable UDCA derivatives may be a novel therapeutic strategy for diarrheal diseases.